Retatrutide is making headlines. What do the latest studies actually show?

Losing a quarter of your starting body weight is a striking result. That is the average reported for the highest-dose group in a newly published retatrutide obesity trial. With two major papers published on September 29, 2026, there is now more to discuss than an exciting company announcement.

This update covers evidence available through September 30, 2026. The strongest new findings concern weight loss, blood sugar and certain obesity-related conditions. They do not establish that retatrutide is right for everyone, that every pound lost is fat, or that it is ready to prescribe.

What is retatrutide?

Retatrutide is an experimental once-weekly injection that activates three hormone receptors: GIP, GLP-1 and glucagon. This is why it is called a triple agonist. Three targets make it scientifically interesting, but receptor count alone cannot tell us how well a treatment will work or how safe it will be. Those questions require clinical trials. Trial program overview.

The new obesity paper: 25% average weight loss

The TRIUMPH-1 paper in the New England Journal of Medicine, published September 29, describes a randomized, double-blind trial with 2,339 adults without diabetes. Participants received retatrutide or placebo for 80 weeks.

• 4 mg group: 17.6% average weight loss.
• 9 mg group: 23.7%.
• 12 mg group: 25.0%.
• Placebo group: 3.9%.

These are the paper's treatment-regimen results, an intention-to-treat analysis that accounts for treatment interruptions or stopping rather than assuming everyone stayed on treatment. For scale, 25% of 240 pounds is 60 pounds. That arithmetic illustrates the percentage; it is not a prediction for an individual.

Why other headlines say 28% or 30%

Lilly's May TRIUMPH-1 announcement highlighted 28.3% at 80 weeks in the 12 mg group, compared with 2.2% on placebo. That is the efficacy estimand: a statistical estimate of what would happen if participants remained on treatment without starting prohibited weight-management therapies. It answers a different question from the 25.0% treatment-regimen estimate.

The 30.3% result came from a 104-week extension. That extension enrolled 532 participants with a starting BMI of at least 35 who completed the initial trial and tolerated their assigned dose; 30.3% was reported for those continuing 12 mg. It is a selected, longer-treated group, not the average for everyone originally randomized. Extension details.

When comparing headlines, keep four things together: the trial population, dose, treatment duration and analysis method. Separating a large percentage from those details makes the evidence sound more universal than it is.

The other new paper: obesity with type 2 diabetes

TRIUMPH-2, published in The Lancet on September 29, randomized 1,152 adults with type 2 diabetes and a BMI of at least 27. At 80 weeks, the treatment-regimen analysis showed average weight reductions of 11.9%, 16.8% and 18.8% in the 4 mg, 9 mg and 12 mg groups, compared with 5.1% on placebo.

The 20.8% figure in Lilly's announcement is the 12 mg efficacy-estimand result, compared with 4.0% on placebo. The same announcement reported average A1C reductions of 1.4 to 1.6 percentage points across doses, versus 0.2 points on placebo. A1C reflects longer-term blood sugar. Reaching a normal A1C while receiving treatment does not, by itself, establish a permanent cure for diabetes. September 29 results.

The research goes beyond the scale

TRIUMPH-1 also included participants with knee osteoarthritis and obstructive sleep apnea. The newly published paper reports improvements in knee pain and fewer apnea-hypopnea events, which are episodes of interrupted or reduced breathing during sleep. These findings concern people with those conditions; they do not mean every person who loses weight can stop existing treatment. TRIUMPH-1 abstract.

A separate diabetes study, TRANSCEND-T2D-1, reported results in June. At 40 weeks, Lilly reported A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% using its efficacy analysis. This studied people whose diabetes was inadequately controlled with diet and exercise alone. It is a different study from the 80-week TRIUMPH-2 trial. June results.

There is an important limit to the heart-health story. In July, Lilly reported 22.6% weight loss versus 3.2% with placebo in TRIUMPH-3, which studied severe obesity and established cardiovascular disease, with or without diabetes. Those were efficacy-estimand results at 80 weeks. However, the reported cardiovascular-event analyses did not establish a statistically significant reduction in major cardiovascular events. Improvements in weight or blood pressure are not the same as proving fewer heart attacks or strokes. TRIUMPH-3 results and confidence intervals.

Side effects deserve space beside the big numbers

In TRIUMPH-2, gastrointestinal problems were common. At 12 mg, about 34% reported diarrhea and 28% nausea, versus 13% and 8% on placebo. Low blood pressure and dysesthesia, an altered or unpleasant sensation, were also more frequent with retatrutide. About 8% in the 12 mg group permanently stopped treatment because of adverse events or death, compared with about 5% on placebo; investigators judged the reported deaths unrelated to treatment. Lancet safety results.

These are supervised trials with eligibility rules, monitoring and controlled study medication. Their findings cannot establish the safety of a vial bought online, or tell us everything about rare harms and many years of use. Trial doses in this article describe the research, not a dosing guide.

Can you get it now?

As of this update, there is no FDA-approved retatrutide product. The FDA warns against unapproved products marketed for weight loss, including retatrutide sold as “research” material, and says retatrutide cannot be used in compounding under federal law. Online availability is not evidence of approval, purity or safe dosing. Discuss currently approved options or legitimate trial participation with a qualified clinician rather than treating social-media dosing advice as medical care.

What this means for your progress

The new publications make the evidence more substantial: large randomized trials show meaningful weight reduction, including in people with type 2 diabetes. But comparisons with semaglutide, tirzepatide or bariatric surgery need appropriate direct evidence. A leaderboard assembled from separate trials cannot establish which treatment is best.

For AddisBody readers, the practical message is to look beyond a single scale number. Keep strength, food quality, movement and day-to-day function in view through your New Body Loop. These trials do not show that medication replaces those habits or that the weight lost is entirely body fat. If medication becomes part of your care, build the routine with your clinician.